Fulcrum Holders Would Keep About 5% Of Combined Company Plus A Cash Dividend Under Slate Merger
An amended S-4 shows Slate holders and new investors taking the rest, with a dividend of about $270 million paid before closing.
Existing Fulcrum Therapeutics holders would own about 5.0% of the combined company after its all-stock reverse merger with private Slate Medicines, according to an amended S-4 registration statement filed Thursday. They would also receive a pre-closing cash dividend of about $270 million, with an estimated range of $260 million to $280 million.
What the amended S-4 says
Pre-merger Slate holders would own about 55.9% on a fully diluted basis, and investors in a concurrent $245 million financing about 39.1%. The estimated exchange ratio is about 24.8186 Fulcrum shares per Slate share, before a reverse split.
The filing puts Slate's value at $350 million. Investor commitments include Forbion at $60 million, RA Capital at $50 million, Frazier at $50 million, Deep Track at $45 million and Foresite at $5 million.
The ratio is tied to Fulcrum's net cash, not its share price. There is no collar and no price-based termination right. Fulcrum's closing price was $3.74 on August 14, and the filing says deal value moves with the stock. A net cash shortfall below $20.3 million would raise Slate's share and cut Fulcrum's.
The merged company would be a clinical-stage migraine business named Slate Medicines, trading as SLTE instead of FULC. Pro forma cash was $394.8 million at June 30, and management expects it to fund operations into 2029. Pro forma adjustments include a $26.6 million one-time stock compensation expense.
How Fulcrum got here
Fulcrum discontinued pociredir in June after FDA concerns about its safety-benefit balance, and cut 85% of its workforce, the filing says. It now has 8 employees.
Its board ran an outreach to 62 parties and concluded that no alternative, including liquidation, a tender offer or an asset sale, was likely to create more value. A dissolution analysis showed about $3.71 per share initially, plus $0.10 in 2028 and $0.10 in 2029. The merger consideration was valued at about $3.93 per share. Leerink Partners gave a fairness opinion dated August 16.
Law firm Kaplan Fox has said publicly that it is investigating potential securities law violations at Fulcrum.
Control, risks and fees
All five directors would be Slate designees, and all current Fulcrum directors would resign. Gregory Oakes would be CEO, Neil Buckley president and chief operating officer, and John W. Umstead V chief financial officer. Fulcrum's executives are terminated at closing with severance of about $3.0 million for the CEO and about $0.9 million each for the other two.
Slate's lead asset, SLTE-1009, started an early-stage trial in Australia in August, with data expected in mid-2027. The filing calls it untested in humans and notes competition from Lundbeck's bocunebart, now in late-stage trials.
Fulcrum would pay Slate a $10 million termination fee in specified cases, and Slate would pay Fulcrum $15 million.
What is still open
The special meeting date, record date and reverse split ratio are blank. The deal needs SEC effectiveness of the registration statement and Nasdaq listing approval. The antitrust waiting period expired September 28.
Fulcrum holders vote on the share issuance and the reverse split, which are conditioned on each other. The board unanimously recommends a vote in favor.
Closing is expected in the fourth quarter of 2026, and the merger agreement's outside date is February 28, 2027.
